Michael S. Cookson, MD, MMHC, FACS, discusses how Anktiva’s expanded FDA approval may broaden bladder-preserving treatment options for BCG-unresponsive papillary-only NMIBC.
Opinion|Videos|February 28, 2026
Considerations for integrating immunotherapy into earlier stages of bladder cancer
Author(s)Kristen R. Scarpato, MD, MPH
Fact checked by: Hannah Clarke
Kristen R. Scarpato, MD, MPH, discusses the potential role of emerging immunotherapy-based combinations in the treatment of BCG-naive, high-risk non–muscle invasive bladder cancer.
Advertisement
In the following video, Kristen R. Scarpato, MD, MPH, discusses the potential role of emerging immunotherapy-based combinations in the treatment of BCG-naive, high-risk non–muscle invasive bladder cancer (NMIBC). Scarpato is an associate professor of urology at Vanderbilt University Medical Center in Nashville, Tennessee.
Advertisement
Related to this article
Sandip M. Prasad, MD, MPhil, discusses the safety profile of mitomycin intravesical solution, including common adverse events and patient counseling during chemoablation for NMIBC.
Sandip M. Prasad, MD, MPhil, discusses 3-year ENVISION trial data showing durable responses with mitomycin intravesical solution for recurrent LG-IR-NMIBC.
Armine K. Smith, MD, discusses sexual health counseling, sex-specific considerations, and organ-preserving approaches for patients undergoing radical cystectomy.
Timothy N. Clinton, MD, recaps bladder cancer data from the 2026 AUA Northeastern Section meeting, including BOND-003 cretostimogene results and safety data on mitomycin intravesical solution.
At a median follow-up of 60.9 months, median EFS was 74.1 months in the pembrolizumab arm and not reached in the placebo arm.
Kim Chi, MD, FRCPC, discusses the rationale and design of the phase 3 KLK2-comPAS trial evaluating pasritamig alone and in combination with JNJ-9401 in patients with mCRPC.
Engy Habashy, MD, discusses key takeaways from the 2025 AUA GSM guideline, including the role of androgens and hormonal therapies in managing genitourinary syndrome of menopause.
Advertisement
Advertisement
Trending on Urology Times
1
Darolutamide associated with less cognitive change than enzalutamide in prostate cancer
2
ESMO 2026: Key presentations across genitourinary oncology
3
KLK2-comPAS trial explores dual T-cell engagement in mCRPC
4
Gedatolisib plus darolutamide shows preliminary activity in mCRPC
5